- Home
- CYTH
as 02-21-2025 4:00pm EST
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
| Founded: | 1990 | Country: | United States |
| Employees: | N/A | City: | GAINESVILLE |
| Market Cap: | 31.9M | IPO Year: | N/A |
| Target Price: | $0.95 | AVG Volume (30 days): | 4.5M |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.55 - $1.79 | Next Earning Date: | 03-17-2025 |
| Revenue: | $870,725 | Revenue Growth: | -8.52% |
| Revenue Growth (this year): | -8.43% | Revenue Growth (next year): | 24.49% |
Latest Cyclo Therapeutics Inc. News
CYTH Breaking Stock News: Dive into CYTH Ticker-Specific Updates for Smart Investing
Business Wire
15 days ago
Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)
Business Wire
a month ago
Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025
GlobeNewswire
2 months ago
Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results
Business Wire
3 months ago
Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
3 months ago
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
GlobeNewswire
4 months ago
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
Business Wire
6 months ago
Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)
GlobeNewswire
6 months ago
Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement
Compare CYTH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CYTH Cyclo Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.